《比较对外汉语教材（对越南）在编写中的问题及学生学习方法的问题》由会员分享，可在线阅读，更多相关《比较对外汉语教材（对越南）在编写中的问题及学生学习方法的问题（104页珍藏版）》请在金锄头文库上搜索。
1、Results of Operations (amounts in thousands unless otherwise noted)经营业绩（单位：除非另有说明）Revenues:收入Our sources of revenue during the years ended December 31, 2011, 2010 and 2009, included our License Agreement with Salix,Transition Agreement with Wyeth, our License Agreement with Ono, our research grants
2、from the NIH and, to a small extent, our sale ofresearch reagents.2011 年 12 月 31 日止年度，2010 年和 2009 年，我们的收入来源，包括我们与柳许可协议，和惠氏的过渡协议，我们与小野的许可协议，我们的研究资助，由美国国立卫生研究院，并在小范围内，我们销售研究试剂。Collaboration revenue:合作收入Salix Collaboration. During the year ended December 31, 2011, we recognized $75,091 of revenue from
3、 Salix, which includes$59,634 from the $60,000 upfront cash payment under the License Agreement, $225 in respect of Salix ex-U.S. sublicensee revenue and$15,232 as reimbursement of our expenses, including $2,172 of manufacturing supplies, in accordance with the License Agreement. As ofDecember 31, 2
4、011, $204 and $162 are recorded in deferred revenue current and long-term, respectively.Wyeth Collaboration. During the years ended December 31, 2011 and 2010, we recognized $1,630 and $1,383, respectively, ofrevenue from Wyeth, as reimbursement of our expenses under the 2009 Transition Agreement.Du
5、ring the years ended December 31, 2010 and 2009, we recognized $1,383 and $29,298, respectively, of revenue from Wyeth,consisting of (i) $0 and $14,562, respectively, of the $60,000 upfront payment we received upon entering into our 2005 collaboration, (ii) $0and $4,736, respectively, as reimburseme
6、nt of our development expenses, and (iii) $1,383 and $10,000, respectively, as reimbursement of ourexpenses under the 2009 Transition Agreement.http:/ Collaboration. During the years ended December 31, 2011 and 2010, we recognized $43 and $30, respectively, ofreimbursement revenue for activities req
7、uested by Ono.我们认识到，二零一一年及二零一零年十二月三十一日止期间，$43和$30，分别，小野合作补偿收入所要求的小野的活动。During the years ended December 31, 2010 and 2009, we recognized $30 and $53, respectively, of reimbursement revenue foractivities requested by Ono and in 2009 recognized the $15,000 upfront payment as revenue, due to satisfying
8、our performance obligations2010年和 2009 年截至 12 月 31.期间，我们认识到在 30 和 53 美元，美元，分别报销的收入由于要满足我们的性能义务。活动要求小野并于2009 年确认为收入 1.5 万美元的首期付款。Royalty income. We began earning royalties from net sales by Wyeth of subcutaneous RELISTOR in June 2008. Under our 2009Transition Agreement, Wyeth continued to distribute
9、RELISTOR in the U.S. until April 1, 2011, in Europe until October 1, 2011, and inAustralia until December 1, 2011, at which times Salix assumed those responsibilities. Royalties due to us during 2011 are attributable only toSalix net sales in those territories from the date in which Salix assumed re
10、sponsibility, the basis for 2011 royalty income. From April 1, 2011 toDecember 31, 2011, we earned royalty income of $3,046 based on net sales of RELISTOR reported by Salix or its sublicensees.During the years ended December 31, 2010 and 2009, royalties of $1,826 and $1,853, http:/ respectively, wer
11、e owed to us based on the netsales of RELISTOR reported by Wyeth and we recognized royalty revenue of $1,826 and $2,372, respectively. During the fourth quarter of2010, no royalties were payable to us.在十二月三十一日止，2010 年和 2009 年，分别 1826 美元 1853 美元，特许权使用费，被拖欠的基础上的纯销售的 RELISTOR 报告由惠氏公司和我们确认使用费收入，分别，1826
12、美元 2372 美元。在第四季度 of2010，没有特许权使用费支付给我们。Results of Operations (amounts in thousands unless otherwise noted)经营业绩（单位：除非另有说明）Revenues:收入Our sources of revenue during the years ended December 31, 2011, 2010 and 2009, included our License Agreement with Salix,Transition Agreement with Wyeth, our License Ag
13、reement with Ono, our research grants from the NIH and, to a small extent, our sale ofresearch reagents.2011 年 12 月 31 日止年度，2010 年和 2009 年，我们的收入来源，包括我们与柳许可协议，和惠氏的过渡协议，我们与小野的许可协议，我们的研究资助，由美国国立卫生研究院，并在小范围内，我们销售研究试剂。Collaboration revenue:合作收入Salix Collaboration. During the year ended December 31, 2011,
14、 we recognized $75,091 of revenue from Salix, which includes$59,634 from the $60,000 upfront cash payment under the License Agreement, $225 in respect of Salix ex-U.S. sublicensee revenue and$15,232 as reimbursement of our expenses, including $2,172 of manufacturing supplies, in accordance with the
15、License Agreement. As ofDecember 31, 2011, $204 and $162 are recorded in deferred revenue current and long-term, respectively.Wyeth Collaboration. During the years ended December 31, 2011 and 2010, we recognized $1,630 and $1,383, respectively, ofrevenue from Wyeth, as reimbursement of our expenses
16、under the 2009 Transition Agreement.During the years ended December 31, 2010 and 2009, we recognized $1,383 and $29,298, respectively, of revenue from Wyeth,consisting of (i) $0 and $14,562, respectively, of the $60,000 upfront payment we received upon entering into our 2005 collaboration, (ii) $0and $4,736, respectively, as reimbursement of our development expenses, and (iii) $1,383 and $10,000, respectively, as reimbursement of ourexpen
